New therapeutic strategy of fludarabine-resistant relapsed and refractory chronic lymphocytic leukemia / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 520-523, 2013.
Article
em Zh
| WPRIM
| ID: wpr-474528
Biblioteca responsável:
WPRO
ABSTRACT
Chronic lymphocytic leukemia (CLL) remains an incurable disease.Rituximab and fludarabine are two of the most effective agents in CLL update.Despite the widespread use of highly effective chemoimmunotherapy,fludarabine-refractory CLL remains a challenging problem associated with poor overall survival.Approved therapeutic options for these patients remain limited.Fortunately,allogenetic stem cell transplantation (allo-SCT) and several novel targeted therapeutics in clinical trails hold promise of significant benefit for these patients' population.This review discusses the activity of available and novel targeted therapeutics besides allo-SCT in fludarabine-refractory or fludarabine-resistant CLL.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Journal of Leukemia & Lymphoma
Ano de publicação:
2013
Tipo de documento:
Article